Unknown

Dataset Information

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters.


ABSTRACT:

Background

Radium-223 dichloride (Ra-223) is now frequently used to treat prostate cancer that has metastasized to bone, although patient selection continues to be suboptimal for determining who will benefit most from this novel treatment modality.

Materials and methods

Seventy-nine patients with metastatic castration-resistant prostate cancer (mCRPC) were treated with Ra-223 from 2012 to 2016. The burden of skeletal metastasis was determined for each using the Bone Scan Index (BSI) as a ratio of diseased to normal bone. Clinical, laboratory, and survival data were collected and examined for associations with BSI, and treatment tolerability was assessed.

Results

Chemotherapy-naïve patients were significantly more likely to complete the full course of treatment. Median

SUBMITTER: Shariftabrizi A 

PROVIDER: S-EPMC10020806 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature